Is Soni Medicare overvalued or undervalued?

As of 26 June 2025, Soni Medicare's valuation grade has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, especially when compared to its peers in the hospital industry. Key ratios include a PE ratio of -20.47, an EV to EBITDA of 23.19, and a ROCE of 7.65%.
In comparison to peers, Soni Medicare's valuation stands out; for instance, Max Healthcare has a PE ratio of 108.68 and an EV to EBITDA of 67.85, while Apollo Hospitals shows a PE of 70.6 and an EV to EBITDA of 35.46. The stark contrast in these ratios suggests that Soni Medicare is undervalued relative to its competitors. Additionally, the company's stock has outperformed the Sensex over the past year, with a return of 78.9% compared to the Sensex's 6.46%, reinforcing the notion of its undervaluation.